RaQualia Pharma Inc
TSE:4579
RaQualia Pharma Inc
RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. The company is headquartered in Nagoya, Aichi-Ken and currently employs 67 full-time employees. The company went IPO on 2011-07-20. The firm is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The firm is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.
RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. The company is headquartered in Nagoya, Aichi-Ken and currently employs 67 full-time employees. The company went IPO on 2011-07-20. The firm is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The firm is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.